Rak S, Jacobson M R, Sudderick R M, Masuyama K, Juliusson S, Kay A B, Hamid Q, Löwhagen O, Durham S R
Department of Allergy and Clinical Immunology, National Heart and Lung Institute, London, UK.
Clin Exp Allergy. 1994 Oct;24(10):930-9. doi: 10.1111/j.1365-2222.1994.tb02724.x.
We have examined the effect of prolonged treatment with topical corticosteroid on allergen-induced early and late nasal responses and the associated inflammatory cell infiltrate in grass pollen sensitive allergic rhinitics. Following a randomized double-blind 6 week treatment period with fluticasone propionate 200 micrograms aqueous nasal spray twice daily or matched placebo spray, nasal provocation was performed using Timothy grass pollen extract. Nasal symptoms were recorded at intervals from 0 to 24 h. Nasal biopsies were performed before treatment and at 24 h after allergen and processed for immunohistology. When corticosteroid-treated patients were compared with the placebo group there was an approximately 50% decrease in the size of the early (0-60 min) response and almost complete inhibition of late (1-24 h) nasal symptoms after allergen challenge. After allergen challenge markedly fewer T lymphocytes and CD25+ (interleukin-2 receptor bearing) cells were observed in both the epithelium and submucosa in fluticasone treated patients compared with the placebo group. Significantly less total and activated eosinophils were observed, particularly within the nasal epithelium. Submucosal mast cell counts were decreased, whereas increased numbers of submucosal neutrophils were observed. These results confirm that topical corticosteroid treatment inhibits allergen-induced early and late nasal responses. This may possibly occur following a decrease in T lymphocytes and/or mast cells and their products and a consequent reduction in tissue eosinophilia.
我们研究了局部使用皮质类固醇长期治疗对草花粉敏感的变应性鼻炎患者变应原诱导的鼻早期和晚期反应以及相关炎症细胞浸润的影响。在随机双盲的6周治疗期内,患者每天两次使用200微克丙酸氟替卡松水性鼻喷雾剂或匹配的安慰剂喷雾剂,之后使用梯牧草花粉提取物进行鼻激发试验。在0至24小时内定期记录鼻部症状。在治疗前以及变应原激发后24小时进行鼻活检,并进行免疫组织学处理。与安慰剂组相比,皮质类固醇治疗的患者在变应原激发后早期(0 - 60分钟)反应的大小降低了约50%,晚期(1 - 24小时)鼻部症状几乎完全受到抑制。与安慰剂组相比,在丙酸氟替卡松治疗的患者中,变应原激发后在上皮和黏膜下层观察到的T淋巴细胞和CD25 +(携带白细胞介素 - 2受体)细胞明显减少。观察到总的和活化的嗜酸性粒细胞显著减少,尤其是在鼻上皮内。黏膜下肥大细胞计数减少,而黏膜下中性粒细胞数量增加。这些结果证实局部皮质类固醇治疗可抑制变应原诱导的鼻早期和晚期反应。这可能是由于T淋巴细胞和/或肥大细胞及其产物减少,从而导致组织嗜酸性粒细胞减少所致。